Claims for Patent: 8,557,831

Summary for Patent: 8,557,831

Title:	Compositions and methods for treatment and prevention of insulin resistance
Abstract:	Disclosed herein are methods of delaying the onset or treating diabetes that comprises administering a uric acid lowering agent. The inventors have made the remarkable discovery that elevated uric acid levels are not a corollary to insulin resistance, but rather a primary mediator of insulin resistance. Specifically exemplified are methods that involve administering to a patient susceptible to development of diabetes a composition comprising a uric acid lowering agent in a regimen that maintains serum uric acid levels below at least 5.2 to 5.5 mg/dl.
Inventor(s):	Johnson; Richard J. (Gainesville, FL), Nakagawa; Takahiko (Gainesville, FL)
Assignee:	University of Florida Research Foundation, Inc. (Gainesville, FL)
Application Number:	11/572,270
Patent Claims:	1. A method of lowering uric acid levels in a patient suffering from insulin resistance comprising: administering to said patient a composition comprising a uric acid lowering agent according to a regimen effective to maintain said patient's average serum uric acid level at or below 5.5 mg/dl, wherein said uric acid lowering agent is a xanthine oxidase inhibitor, a uricosuric, a uricase, a peqylated uricase, a rasburicase, a urate channel inhibitor, or a URAT-1 blocker, wherein said administering treats said insulin resistance. 2. The method of claim 1, further comprising determining said patient's average serum uric acid prior to said administering. 3. The method of claim 1, wherein said composition is administered over the course of at least one week. 4. The method of claim 1, wherein said composition is administered over the course of at least 2 weeks. 5. The method of claim 1, wherein said composition is administered over the course of at least 4 weeks. 6. The method of claim 1, wherein said composition is administered according to a regimen to maintain the average serum uric acid level equal to or below 5.5 mg/dl for at least 2 weeks. 7. The method of claim 6, wherein regimen is designed to maintain the average serum uric acid level equal to or below 5.5 mg/dl for at least 4 weeks. 8. The method of claim 6, wherein regimen is designed to maintain the average serum uric acid level equal to or below 5.5 mg/dl for at least 8 weeks. 9. The method of claim 6, wherein regimen is designed to maintain the average serum uric acid level equal to or below 5.5 mg/dl for at least 24 weeks. 10. The method of claim 6, wherein regimen is designed to maintain the average serum uric acid level equal to or below 5.5 mg/dl for at least 2 years. 11. The method of claim 1, wherein said composition is administered according to a regimen to maintain average serum uric acid levels between 4.5 mg/dl to 5.5 mg/dl for at least 12 weeks. 12. The method of claim 11, wherein said composition is administered according to a regimen to maintain average serum uric acid levels between 4.5 mg/dl to 5.5 mg/dl for at least 1 year. 13. A method of lowering uric acid levels in a patient suffering from insulin resistance comprising: determining said patient's average serum uric acid level; and administering to said patient a composition comprising a uric acid lowering agent according to a regimen effective to maintain said patient's average serum uric acid level between 4.5 mg/dl and 5.5 mg/dl for at least 4 weeks, wherein said uric acid lowering agent is a xanthine oxidase inhibitor, a uricosuric, a uricase, a peqylated uricase, a rasburicase, a urate channel inhibitor, or a URAT-1 blocker, wherein said administering treats said insulin resistance. 14. The method of claim 13, wherein said administering occurs according to a regimen effective to maintain said patient's average serum uric acid level between 4.5 mg/dl and 5.5 mg/dl for at least 12 weeks. 15. The method of claim 13, wherein said administering occurs according to a regimen effective to maintain said patient's average serum uric acid level between about 4.5 mg/dl and 5.5 mg/dl for at least 36 weeks. 16. A method of lowering uric acid levels in a patient suffering from insulin resistance comprising administering to said patient a composition comprising a uric acid lowering agent according to a regimen effective to maintain said patient's average serum uric acid level between 4.5 mg/dl and 5.5 mg/dl for at least 2 weeks, wherein said uric acid lowering agent is a xanthine oxidase inhibitor, a uricosuric, a uricase, a pegylated uricase, a rasburicase, a urate channel inhibitor, or a URAT-1 blocker, wherein said administering treats said insulin resistance. 17. The method of claim 1, wherein said uric acid lowering agent is a xanthine oxidase inhibitor. 18. The method of claim 17, wherein said xanthine oxidase inhibitor is febuxostat. 19. The method of claim 1, wherein said uric acid lowering agent is benziodarone, benzbromarone or probenecid. 20. The method of claim 1, wherein said uric acid lowering agent is a urate channel inhibitor. 21. The method of claim 1, wherein said uric acid lowering agent is a URAT-1 blocker.

Details for Patent 8,557,831

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946	07/12/2002		2024-07-21
Sanofi-aventis U.s. Llc	ELITEK	rasburicase	For Injection	103946	01/06/2006		2024-07-21